<DOC>
	<DOCNO>NCT00624442</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacodynamics CK-1827452 infusion patient stable heart failure .</brief_summary>
	<brief_title>A Study CK-1827452 Infusion Stable Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion Criteria 1 . Patient male , female nonchildbearing potential ( two year postmenopausal surgically sterilize ) 2 . Female patient must negative urine pregnancy test prior entry study 3 . Patient 18 year old great 4 . Patient give sign informed consent 5 . Patient consider suitable health opinion investigator , determine : A prestudy physical examination clinical abnormality opinion investigator would preclude participation study physical symptom sign consistent stable heart failure An electrocardiogram ( ECG ) abnormalities opinion investigator would impair assessment stop criterion 6 . Patient prestudy clinical laboratory finding within normal range , outside normal range , preclude participation study opinion investigator ( see Exclusion Criteria , , exception ) 7 . Patient document diagnosis heart failure ejection fraction le 40 % 8 . Patient stable dose beta blocker ACE ( angiotensinconverting enzyme ) inhibitor ARB ( angiotensin II receptor blocker ) least 4 week . If prescribe , diuretic must administer accord consistent regimen least 4 week 9 . Patient currently sinus rhythm 10 . Patient interpretable echocardiographic image screen echocardiogram Exclusion Criteria 1 . Patient hospitalize heart failure , myocardial infarction , coronary revascularization , another cardiac indication within last 6 week 2 . Patient current history alcohol use opinion investigator would preclude participation study 3 . Patient current history drug abuse 4 . Patient donate blood blood product within 30 day prior screen 5 . Patient Canadian Cardiovascular Society ( CCS ) Class III IV angina 6 . Patient significant obstructive valvular disease significant congenital heart disease 7 . Patient valve replacement 8 . Patient pacemaker dependent 9 . Patient chronic antiarrhythmic therapy , exception amiodarone 10 . Patient currently take , take last 7 day , CYP3A4 inhibitor inducer medication 11 . Patient history hypertrophic obstructive cardiomyopathy 12 . Patient weigh &gt; 120 kg 13 . Patient supine rest systolic blood pressure &lt; 95 mmHg 3 minute rest 14 . Patient supine rest heart rate ≥ 100 beat per minute 3 minute rest 15 . Patient Modification Diet Renal Disease ( MDRD ) estimate Glomerular Filtration Rate ( GFR ) ≤ 35 ml/min/1.73 m2 16 . Patient potassium &lt; 3.5 mEq/L &gt; 5.5 mEq/L 17 . Patient sodium ≤ 133 mEq/L 18 . Patient urea &gt; 15 mmole/L 19 . Patient troponin I T screen detectable investigative site 's clinical laboratory 20 . Patient hemoglobin &lt; 11 gm/dL male &lt; 10 gm/dL female 21 . Patient alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase ( ALKP ) total bilirubin ( TBILI ) &gt; 3 time upper limit normal 22 . Patient , opinion investigator , suitable participate study 23 . Patient participate clinical study investigational drug within three month prior first day dose exception coronary stent study Patient ever receive CK1827452</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>